Phase II study of ifosfamide+doxorubicin in patients with advanced synovial sarcomas (E1793): A trial of the Eastern Cooperative Oncology Group

Sarcoma

Volumn 7, Issue 1, 2003, Pages 9-11

  Edmonson, John H ^a   Ryan, Louise M ^b   Falkson, Carla I ^c   Hicks, David G ^d   Blum, Ronald H ^e  

^a MAYO CLINIC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d ROCHESTER GENERAL HOSPITAL   (United States)

^e BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SYNOVIAL SARCOMA; TREATMENT OUTCOME;

EID: 0038293019     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1357714031000114156     Document Type: Article

References (10)

1. Chang AE, Rosenberg SA, Glatstein EJ, Antman KH. Sarcomas of soft tissue. In: Devita VT Jr, Hellman S, Rosenberg SA, eds. Cancer Principals and Practice of Oncology, 3rd Edition. Philadelphia, PA: J.B. Lippincott Co. 1989; 1384.
2. Shiraki M, Enterline HT, Brooks JJ, Cooper NS, Hirschl S, Roth JA, Rao UN, Enzinger FM, Amato DA, Borden EC. Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group experience. Cancer 1989; 64: 484-490.
3. Edmonson J, Ryan L, Blum R, Brooks JSJ, Shiraki M, Frytak S, Parkinson DR. Phase III Eastern Cooperative Oncology Group study of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin plus doxorubicin plus cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-1275.
4. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckhardt J, Holmes C, Fu YS. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 1994; 73: 2506-2511.
5. Pappo AS, Fontanesi J, Luo X, Rao BN, Parham DM, Hurwitz C, Avery L, Pratt CB. Synovial sarcoma in children and adolescents: the St. Jude Children's Research Hospital experience. J Clin Oncol 1994; 12: 2360-2366.
6. Lewis JJ, Antonescu CR, Leung DHY, Blumberg D, Healey JH, Woodruff JM, Brennan MF. Synovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremity. J Clin Oncol 2000; 18: 2087-2094.
7. Trassard M, LeDoussal V, Hacène K, Terrier P, Ranchère D, Guillou L, Fiche M, Collin F, Vilain MO, Bertrand G, Jacquemier J, Sastre-Garau X, Binh Bui N, Bonichon F, Coindre JM. Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol 2001; 19: 525-534.
8. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157.
9. Landyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JSJ, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002; 62: 135-140.
10. Heinrich MC, Blanke CD, Drucker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-1703.